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Oxidative stress plays a key role in the pathogenesis of hepatic ischemia/reperfusion (I/R)-
induced injury, one of the leading causes of liver damage post-surgical intervention,
trauma and transplantation. This study aimed to evaluate the protective effect of nebivolol
and chrysin against I/R-induced liver injury via their vasodilator and antioxidant effects,
respectively. Adult male Wister rats received nebivolol (5 mg/kg) and/or chrysin (25 mg/kg)
by oral gavage daily for one week then subjected to ischemia via clamping the portal triad
for 30 min then reperfusion for 30 min. Liver function enzymes, alanine transaminase
(ALT) and aspartate transaminase (AST), as well as hepatic Myeloperoxidase (MPO), total
nitrate (NOx), glutathione (GSH) and liver malondialdehyde (MDA) were measured at the
end of the experiment. Liver tissue damage was examined by histopathology. In addition,
the expression levels of nitric oxide synthase (NOS) subtypes, endothelial (eNOS) and
inducible (iNOS) in liver samples were assessed by Western blotting and confirmed by
immunohistochemical analysis. Both chrysin and nebivolol significantly counteracted I/R-
induced oxidative stress and tissue damage biomarkers. The combination of these agents
caused additive liver protective effect against I/R-induced damage via the up regulation of
nitric oxide expression and the suppression of oxidative stress. Chrysin and nebivolol
combination showed a promising protective effect against I/R-induced liver injury, at least
in part, via decreasing oxidative stress and increasing nitric oxide levels.
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Hepatic ischemia/reperfusion (I/R) injury is a major hepatic
problem that arises in many situations such as liver trans-
plantation, resection, circulatory shock, and post traumatic
interruption of blood supply to liver (Kim et al., 2013). The
release of reactive oxygen species (ROS) underlies the patho-
physiology of the injury during the reperfusion stage which
provokes inflammatory response in the form of activation of
kuppfer cells, inflammatory cytokines and infiltration of leu-
cocytes which, in turn, leads to liver cells damage (Jaeschke,
2006; Schwartz et al., 2013). The activation of Kuppfer cells
leads to the release of ROS such as superoxide, hydroxyl, and
hydrogen peroxide radicals which are the main causes of
tissue damage especially after the release of nitric oxide (NO)
from endothelium upon reperfusion forming peroxynitrite
with oxygen free radicals (Taniai et al., 2004).
In normal liver, there is a delicate balance between NO
vasodilating effect and endothellin (ET) vasoconstricting ef-
fect which controls the vascular rhythm in liver (Jaeschke,
2003; Nakamura et al., 1995). NO is produced in liver by two
subtypes of nitric oxide synthetases; endothelial nitric oxide
synthetase (eNOS) and inducible nitric oxide synthetase
(iNOS) (Tian et al., 2010). eNOS is produced naturally by
endothelium and it is responsible for maintaining blood sup-
ply to the liver. While the production of iNOS is induced in the
endothelial, hepatocyte and other hepatic cells under special
conditions such as decreased blood supply or increased
vasoconstriction injury (Serracino-Inglott et al., 2001). iNOS is
responsible for the vasodilatation of liver sinusoid and
consequent hypotension and stroke following the hepatic
injury (Serracino-Inglott et al., 2001). Thus, we hypothesized
that the use of some agents with vasodilating effects before
the ischemic stage would increase the amount of NO pro-
duced from eNOS and decrease the induction of iNOS during
the reperfusion stage. In addition, the use of agents with anti-
oxidant activities should be beneficial in the treatment of
hepatic injury following I/R.
In the current study, we assessed the potential protective
effect of an NO producing drug such as nebivolol and an
antioxidant such as chrysin against I/R-induced liver injury in
rats. Nebivolol is a long acting vasodilating b1-blocker with
some b3 agonist activity (Chlopicki et al., 2002; Feng et al., 2012;
Gupta andWright, 2008; Maffei and Lembo, 2009). It acts as NO
producer by activating soluble guanylate cyclase which in-
creases cGMP. cGMP acts as a smooth muscle relaxant in
endothelium and may alleviate I/R-induced injury (Parenti
et al., 2000; Sobocanec et al., 2006). Chrysin is a natural
flavone which is used as a dietary supplement found in many
plants, honey, and propolis (Williams et al., 1997). It has many
reported biological activities such as anti-oxidant (Lapidot
et al., 2002; Pushpavalli et al., 2010a), anti-inflammatory
(Gresa-Arribas et al., 2010), Antidiabetic (Lukacı´nova et al.,
2008), anxiolytic properties (Wolfman et al., 1994) as well as
vasorelaxant effects (Duarte et al., 2001).
In an attempt to elaborate the mechanism of the potential
hepatoprotective effects of nebivolol and chrysin, we inves-
tigated its effect on the redox status of liver rats by assessing
the levels of lipid peroxides, NO and protein thiols. In addition,the expression levels of nitric oxide synthetase subtypes
(eNOS and iNOS) in liver samples were assessed by Western
blotting.2. Materials and methods
2.1. Animals
Adult male Wister rats weighing 220e250 gm were used for
performing this experiment and were obtained from national
research center (Giza, Egypt), they were housed in cages, 10
animal per each cage and maintained at room temperature
and 12/12 h lightedark cycle and free access ofwater and food.
All animal use and handling were done in accordance with
protocols approved by the Faculty of Pharmacy, Beni-Suef
University Animal Care and Use Committee.
2.2. Surgical procedure and experimental design
Fifty rats were used for performing this study divided into 5
groups, the first one receiving dimethyl sulphoxide (DMSO) in
saline and kept as control, second group is kept as ischemic
control given DMSO in saline, third group was given chrysin
(25fmg/kg/day) (Pushpavalli et al., 2010b), fourth group was
given nebivolol (5 mg/kg/day) (Heeba and El-Hanafy, 2012),
fifth group was given combination (chrysin plus nebivolol). All
rats were pretreated with drugs by oral gavage once daily for 7
consecutive days,after the 30 min of the last dose and over-
night fasting animals were anaesthetized with 70 mg/kg
thiopental sodium (Fouad & Jresat, 2011) and middle laparot-
omy was incised and portal triad (portal vein, hepatic artery,
bile duct) clamped for 30 min (ischemic period) and releasing
the clips for allow reperfusion for another 30 min then the
animal was sacrificed and blood sample collected as well as
liver was excised and median and left lobe was removed for
further biochemical investigations (Dulundu et al., 2007).
2.3. Determination of serum alanine aminotransferase
(ALT), aspartate aminotransferase (AST)
Determination of ALT and AST was performed using the
commercially available diagnostic kits (Randox Laboratories
Ltd., UK) according to the manufacturer instructions. The
assay is based on the measurement of hydrazone derivatives
which are produced by the interaction of alpha oxoglutarate
with alanine and aspartate respectively. The amount of
hydrazone derivative is proportional to the quantity of
released enzyme.
2.4. Determination of oxidative stress biomarkers
Hepatic glutathione (GSH) was measured according the
method described before and expressed as mmol/gm wet tis-
sue (Beutler and West, 1977), hepatic malondialdehyde (MDA)
was measured according to the method of Mihara and
Uchiyama (1978)and expressed as nmol/gm wet tissue
(Mihara and Uchiyama, 1978), hepatic Myeloperoxidase (MPO)
was measured according to the method of Harada et al. (1999)
and expressed as U/gm wet tissue (Harada et al., 1999), and
Table 1 e Effects of nebivolol and/or chrysin on serum
alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) in rats subjected to I/R.
GROUPS ALT(u/l) AST (u/l)
CONTROL 21.7 ± 0.7 103.4 ± 11.2
ISCHEMIC 122.4 ± 4.9a 205.0 ± 13.2a
CHRYSIN 70.4 ± 5.2a,b 126.0 ± 8.1b
NEBIVOLOL 81.4 ± 6.7a,b 166.7 ± 17.1a
NEBIVOLOL & CHRYSIN 61.7 ± 9.4a,b 116.8 ± 11.2b
Each group consist of 6e10 animals.
Values are mean ± SEM.
a Significant from normal at P < 0.05.
b Significant from I/R at P < 0.05.
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Miranda et al. (2001) and expressed as mmol/gm wet tissue
(Miranda et al., 2001).2.5. Histopathology
Autopsy samples were taken from the liver of rats in different
groups and fixed in 10% formol saline for 24 h. Washing was
done in tap water then serial dilutions of alcohol (methyl,
ethyl and absolute ethyl) were used for dehydration. Speci-
mens were cleared in xylene and embedded in paraffin at 56
in hot air oven for 24 h. Paraffin bees wax tissue blocks were
prepared for sectioning at 4 microns thickness by slidge
microtome. The obtained tissue sections were collected on
glass slides, deparaffinized, stained by hematoxylin &eosin
stain for routine examination then examination was done
through the light electric microscope.2.6. Western blotting
Western blottingwas performed essentially as reported before
(Omar et al., 2011). Briefly, proteins were extracted from liver
tissues which were subjected to ischemia, and their concen-
trations were determined by the Bradford assay (Bio-Rad, CA,
USA). Equivalent amounts of proteins were subjected to 10%
SDS polyacrylamide gel electrophoresis. Blots were trans-
ferred onto a nitrocellulose membrane using a semidry
transfer cell. After blocking, the membranes were then incu-
bated with the appropriate primary and then secondary an-
tibodies. The immunoblots were detected using enhanced
chemiluminescence.Table 2 e Effects of nebivolol and/or chrysin on oxidative stres
GROUPS GSH(mg/g wet tissue) MDA(nmol/g we
CONTROL 1.1 ± 0.10 57.5 ± 2.5
ISCHEMIC 0.4 ± 0.02a 123.3 ± 5.8
CHRYSIN 0.9 ± 0.10b 63.9 ± 5.0
NEBIVOLOL 0.7 ± 0.40a,b 56.4 ± 2.6
NEBIVOLOL & CHRYSIN 0.9 ± 0.08b 47.9 ± 3.4
Each group consist of 6e10 animals.
Values are mean ± SEM.
a Significant from normal at P < 0.05.
b Significant from I/R at P < 0.05.2.7. Immunohistochemistry
Liver Samples fixed in paraffin were cutted into 4 mm sections
then deparrafinezed with citrate buffer (pH ¼ 6) (Omar et al.,
2009). Samples were rehydrated in methanol and washed
with phosphate buffered saline bath,samples were treated
with primary antibody for iNOS or eNOS for 1 h then washed
and treated with biotinylated secondary antibody for
20 min,washed,incubated with streptividin peroxidase then
with diaminobenzidine with chromogen,finally slides were
counterstained with hematoxylin and visualized under light
microscope,immunopositive patches colored with red brown
color in the cytoplasm and the nucleus is stained with dark
blue color.
2.8. Statistical analysis
All values of results are expressed as Mean ± SE of means. The
results were analyzed by one way analysis of variance
(ANOVA), followed by Tukey HSD test for multiple compari-
sons using SPSS (version 16). The Differences were considered
significant at P < 0.05.3. Results
3.1. Effect of nebivolol and/or chrysin on liver enzymes
I/R markedly increased serum ALT and AST by 5- and 2-folds
respectively. The rise of these enzymes was inhibited by
prior administration of chrysin, nebivolol or their combina-
tion to 57%, 66% and 50% for ALT and 61%, 80% and 56% for
AST respectively (Table 1).
3.2. Effect of nebivolol and/or chrysin on oxidative stress
biomarkers
I/R injury markedly increased oxidative stress by decreasing
GSH to 33% and increasing MDA, total NITRATE, and MPO to
227%, 225% and 286% respectively as compared to normal
control. Chrysin effectively antagonized I/R-induced depletion
of glutathione by increasing its level to 226%. It decreased
MDA, total NITRATE and MPO by 52%, 75% and 52% respec-
tively as compared to ischemic group. Nebivolol increased
GSH and total NITRATE by 196% and 111% respectively while
decreased MDA and MPO by 45% and 60% respectively ass biomarkers in rats subjected to I/R.
t tissue) NITRATE(mM/g wet tissue) MPO(U/g wet tissue)
1.0 ± 0.04 1.2 ± 0.03
a 2.1 ± 0.10a 3.3 ± 0.12a
b 1.6 ± 0.12a 1.7 ± 0.05a,b
b 2.4 ± 0.15a 2.0 ± 0.03a,b
b 2.3 ± 0.17a 1.5 ± 0.04a,b
Fig. 1 e Photomicrographs (x40) of rat hepatic tissue stained with hematoxylin & eosin (H&E) stain. A) Section from hepatic
tissue of normal rats with normal histological structure of the central vein and surrounding hepatocytes. B) Section of
hepatic tissue of I/R showing Fatty change in diffuse manner all over the hepatocytes. C) Section of hepatic tissue of group
treated with chrysin followed by I/R injury showing fatty liver changes in some of the hepatocyte. D) Section of hepatic
tissue of group treated with nebivolol followed by I/R injury showing congestion in the central and portal vein as well as
sinusoids in association with diffuse kuppfer cells proliferation in between the hepatocytes. E) Section of hepatic tissue of
group treated with combination of chrysin and nebivolol followed by I/R showing very low fatty changes in hepatocyte.
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nebivolol markedly increased GSH content and total NITRATE
by 226% and 111% respectively while decreasedMDA andMPO
by 38% and 46%respectively as compared to ischemic group
(Table 2).3.3. Histopathological evaluation
I/R caused some fatty changes noticed in diffusive manner all
over the hepatocyte with degeneration and vacuolization
(ballooning degeneration) which decreasedwith pretreatment
with chrysin and nebivolol. Congestion in central and portalTable 3 e Effects of nebivolol and/or chrysin on I/R-
induced iNOS and eNOS expression in rat hepatic tissues
measured by Western blotting.
GROUP eNOS(mg/g wet tissue) iNOS(mg/gm wet tissue)
CONTROL 1.4 ± 0.15 0.1 ± 0.01
ISCHEMIC 0.3 ± 0.06a 0.8 ± 0.09a
CHRYSIN 0.7 ± 0.05a 0.7 ± 0.06a
NEBIVOLOL 0.7 ± 0.07a 0.7 ± 0.06a
NEBIVOLOL
&CHRYSIN
1.0 ± 0.15a,b 0.3 ± 0.04a,b
Each group consist of 6e10 animals.
Values are mean ± SEM.
a Significant from normal at P < 0.05.
b Significant from I/R at P < 0.05.vein as well as sinusoids with diffusive kuppfer cell prolifer-
ation between the hepatocyte was observed in nebivolol
group. Both fatty changes and congestion were nearly absent
in the combination group (Fig. 1).3.4. Western blotting of iNOS and eNOS
I/R increased the expression of iNOS by about 6-fold as
compared to control group. Pretreatment with chrysin, nebi-
volol or their combination antagonized I/R-induced expres-
sion of iNOS by 83%, 85% and 35% respectively as compared to
ischemic group. With regard to eNOS, I/R group showed a
decrease in the expression of eNOS by 19% as compared to
normal control. Pretreatment with chrysin, nebivolol or their
combination markedly increased the expression of eNOS by
242%, 235% and 350% respectively as compared to ischemic
group (Table 3, Fig. 2).3.5. Immunohistochemistry
Immunohistochemical examination showed that I/R
decreased the immunoreactivity to eNOS which increased in
the groups pretreated with nebivolol or chrysin or their com-
bination. eNOS is expressed as brown color in the hepatocyte
cytoplasm as compared to control group (Fig. 3). On the other
hand, I/R increased the immunoreactivity to iNOS which was
counteracted by the nebivolol or chrysin or their combination
as compared to control group (Fig. 4).
Fig. 2 eWestern blots showing the effect of nebivolol and/or chrysin on the expression of iNOS and eNOS in rat liver tissues
subjected to I/R. N ¼ normal control, I/R ¼ ischemia reperfusion, CHR ¼ chrysin, Neb ¼ nebivolol, Mix ¼ combination of
nebivolol and chrysin
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Hepatic ischemiaereperfusion (I/R) is amajor clinical problem
associated with numerous conditions such as liver trans-
plantation, liver resection, hypovolemic shock and cardiac
failure (Gracia-Sancho et al., 2010). Many pharmacological and
clinical research and trials have been done to protect against I/
R-induced liver injury. However, there is a paradox about the
optimal measures and treatments to protect against the post
ischemic hepatocyte damage.
Because of the complicated pathophysiology of I/R-
induced liver injury, it is generally difficult to achieve
optimal treatment or protection using individual medication.
The goal of the current study was to analyze the single and
combined effects of chrysin and nebivolol pretreatment in
preventing liver damage during hepatic I/R injury. Chrysin is
known to counteract oxidative stress and replenish GSH levels
in vitro and in vivo (Lapidot et al., 2002; Pushpavalli et al.,
2010a). On the other hand, nebivolol is a long acting vaso-
dilating b1-blocker which acts as NO producer by activatingFig. 3 e Immunohistochemical staining of the inducible nitric ox
of control group (brown color). B) Ischemic group showing incre
Chrysin group showing decreased intensity of staining relative
decreased intensity of staining compared to ischemic or chrysi
showing decreased intensity of staining compared to ischemicsoluble guanylate cyclase which increases cGMP in vascular
smooth muscles (Parenti et al., 2000; Sobocanec et al., 2006).
Our results indicated that decreased NO during the
ischemic stage and increased ROS during reperfusion stage
are themain causes of I/R-induced injury. Nebivolol decreased
hepatocyte damage and partially restored its functions and
morphology. The protective effect of nebivolol was attributed
to its vasodilator effect via the induction of NO production and
release. These results are in accordance with the reported
activity of nebivolol as a vasodilator b1-blocker (Gao et al.,
1991; Wehland et al., 2012). In addition, the observed antiox-
idant effect of nebivolol in the present study by increasing
hepatic glutathione level and the decreasing MDA, MPO and
total nitrate was also reported by Munzel and Gori (2009).
Many studies have shown that nebivolol acts as anti-oxidant
via its ability to scavenge oxygen free radicals (de Groot
et al., 2004; Erdamar et al., 2009).
Kuppfer cell edema and damaged hepatocyte release ROS
and pro-inflammatory cytokines such as TNF-alpha IL-1, and
IL-8 (Mehany et al., 2013; Witthaut et al., 1994). These media-
tors activate the chemotaxis of neutrophils which, in-turn,ide synthase (iNOS) in rat hepatic tissue (x160). A) Staining
ased intensity of staining and the expression of iNOS. C)
to the ischemic group. D) Nebivolol group showing
n group. E) Combination of nebivolol and chrysin group
group.
Fig. 4 e Immunohistochemical staining of constitutive nitric oxide synthase (eNOS) of rat hepatic tissue subjected to I/R
(x160). A) Staining of control group (brown color). B) Ischemic group showing the lowest color intensity and the lowest
expression of eNOS in the hepatic tissue. C) Chrysin group showing increased intensity of staining relative to ischemic
group. D) Nebivolol group showing increased intensity of staining relative to ischemic group. E) Combination of chrysin and
nebivolol treated group showing increased intensity of staining relative ischemic group.
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from Kuppfer cells and consequently cause more hepatocyte
damage (Mehany et al., 2013; Perry et al., 2011; Witthaut et al.,
1994).
In the current study, chrysin protected hepatocyte from I/
R-induced injury via its antioxidant activity which was evi-
denced by decreased lipid peroxidation and nitrate production
as well as increased protein thiols in the treated animals. The
antioxidant effect of chrysin is attributed to the hydroxyl
group in carbon 5 which give chrysin complexing activities for
free radicals (Torel et al., 1986). In addition, chrysin decreased
neutrophils adhesion to endothelial cells which was evi-
denced by decreased MPO activity. These results match those
reported by other groups considering chrysin antioxidant ac-
tivity both in vitro and in vivo (Anand et al., 2012; Vollmar et al.,
1994). Furthermore, chrysin inhibited pro-inflammatory cy-
tokines and prevented inflammation by inhibiting TNF-alpha
and NF-kB. These results are in accordance with the re-
ported anti-inflammatory activity of chrysin and its ability to
release NO from the endothelial cells (Ha et al., 2010;
Harasstani et al., 2010; Lee et al., 2009; Parenti et al., 2000).
The combination of nebivolol and chrysin showed more
significant hepatocyte protective effect than the single treat-
ment. The additive effect could be due to the ability of nebi-
volol to decrease the injury during the ischemic stage and
chrysin to decrease the damage during the reperfusion stage.
In conclusion, preconditioning with nebivolol and/or
chrysin had a beneficial effect in protecting the rat liver
against I/R-induced injury. These protective effects could be
beneficial in certain clinical conditions such as cardiovascular
disorders associated with liver failure and waiting for trans-
plantation. Themajor limitation for the current study could be
the possible decrease of nebivolol metabolism in chronic liver
disorders (Hilas and Ezzo, 2009). This combination mayprovide a new option for the prevention of I/R-induced liver
injury.r e f e r e n c e s
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